EPCAM and cancer: Taken together these studies suggest that subcellular nuclear and cytoplasmic localization of Ep-ICD may be dependent on the cancer type and warrant in-depth studies in different cancers to explore their clinical utility both as prognostic markers and as predictors of response to EpCAM directed therapies.